Meningococcal Group B Vaccine 4 strain

Meningococcal Group B Vaccine 4 strain Brand Name– TRUMENBA

What is Meningococcal Group B Vaccine 4 strain

The meningococcal vaccine is available as four different formulations: meningococcal polysaccharide vaccine (Menomune); meningococcal polysaccharide diphtheria toxoid conjugate vaccine (Menactra); meningococcal oligosaccharide diphtheria toxoid conjugate vaccine (Menveo); meningococcal recombinant vaccine (Trumenba and Bexsero).

All four vaccines are indicated for the prevention of invasive disease caused by Neisseria meningitis; Menomune, Menactra, and Menveo are active against serogroups A, C, Y, and W-135, while Trumenba and Bexsero are active against serogroup B.

For additional information on other meningococcal vaccines, see Meningococcal Polysaccharide Vaccine (MPSV4) and/or Meningococcal Conjugate Vaccine (MCV4)

Indications

  • meningococcal infection prophylaxis

Side Effects

  1. anaphylactoid reactions
  2. arthralgia
  3. chills
  4. diarrhea
  5. erythema
  6. fatigue
  7. fever
  8. headache
  9. injection site reaction
  10. myalgia
  11. syncope
  12. vomiting

Monitoring Parameters

  • laboratory monitoring not necessary

Contraindications

  • agammaglobulinemia
  • anticoagulant therapy
  • breast-feeding
  • children
  • coagulopathy
  • corticosteroid therapy
  • fever
  • geriatric
  • hemophilia
  • human immunodeficiency virus (HIV) infection
  • hypogammaglobulinemia
  • immunosuppression
  • infants
  • infection
  • neonates
  • neoplastic disease
  • pregnancy
  • radiation therapy
  • severe combined immunodeficiency (SCID)
  • thrombocytopenia

Interactions

  • Ocrelizumab
  • Siponimod